Collaboration Revenue - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	0 Months Ended	3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended		0 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended			0 Months Ended		0 Months Ended		0 Months Ended		3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		0 Months Ended	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		0 Months Ended		3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended	0 Months Ended	3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		0 Months Ended		0 Months Ended	3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended	0 Months Ended	3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended	0 Months Ended										0 Months Ended
	Jul. 26, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014 Upfront and Milestone Payments	Jun. 30, 2013 Upfront and Milestone Payments	Jun. 30, 2014 Upfront and Milestone Payments	Jun. 30, 2013 Upfront and Milestone Payments	Dec. 31, 2013 Upfront and Milestone Payments	Jun. 30, 2014 Research And Development Services	Jun. 30, 2013 Research And Development Services	Jun. 30, 2014 Research And Development Services	Jun. 30, 2013 Research And Development Services	Aug. 06, 2012 Synthetic Biologics Field Two ECC	Aug. 06, 2012 Synthetic Biologics Field Two ECC	Jun. 30, 2014 Synthetic Biologics, Inc.	Jun. 30, 2013 Synthetic Biologics, Inc.	Jun. 30, 2014 Synthetic Biologics, Inc.	Jun. 30, 2013 Synthetic Biologics, Inc.	Jun. 30, 2014 Synthetic Biologics, Inc. Upfront and Milestone Payments	Jun. 30, 2013 Synthetic Biologics, Inc. Upfront and Milestone Payments	Jun. 30, 2014 Synthetic Biologics, Inc. Upfront and Milestone Payments	Jun. 30, 2013 Synthetic Biologics, Inc. Upfront and Milestone Payments	Jun. 30, 2014 Synthetic Biologics, Inc. Research And Development Services	Jun. 30, 2013 Synthetic Biologics, Inc. Research And Development Services	Jun. 30, 2014 Synthetic Biologics, Inc. Research And Development Services	Jun. 30, 2013 Synthetic Biologics, Inc. Research And Development Services	Dec. 17, 2012 Synthetic Biologics, Inc. Research And Development Services	Jun. 05, 2012 Oragenics ECC	Jun. 05, 2012 Oragenics ECC	Sep. 30, 2013 Oragenics Second ECC	Sep. 30, 2013 Oragenics Second ECC	Apr. 30, 2013 Fibrocell Science, Inc.	Oct. 05, 2012 Fibrocell Science, Inc.	Jun. 30, 2014 Fibrocell Science, Inc.	Jun. 30, 2013 Fibrocell Science, Inc.	Jun. 30, 2014 Fibrocell Science, Inc.	Jun. 30, 2013 Fibrocell Science, Inc.	Oct. 05, 2012 Fibrocell Science, Inc.	Jun. 30, 2014 Fibrocell Science, Inc. Upfront and Milestone Payments	Jun. 30, 2013 Fibrocell Science, Inc. Upfront and Milestone Payments	Jun. 30, 2014 Fibrocell Science, Inc. Upfront and Milestone Payments	Jun. 30, 2013 Fibrocell Science, Inc. Upfront and Milestone Payments	Jun. 30, 2014 Fibrocell Science, Inc. Research And Development Services	Jun. 30, 2013 Fibrocell Science, Inc. Research And Development Services	Jun. 30, 2014 Fibrocell Science, Inc. Research And Development Services	Jun. 30, 2013 Fibrocell Science, Inc. Research And Development Services	Mar. 29, 2013 Genopaver, LLC	Jun. 30, 2014 Genopaver, LLC	Jun. 30, 2013 Genopaver, LLC	Jun. 30, 2014 Genopaver, LLC	Jun. 30, 2013 Genopaver, LLC	Jun. 30, 2014 Genopaver, LLC Upfront and Milestone Payments	Jun. 30, 2013 Genopaver, LLC Upfront and Milestone Payments	Jun. 30, 2014 Genopaver, LLC Upfront and Milestone Payments	Jun. 30, 2013 Genopaver, LLC Upfront and Milestone Payments	Jun. 30, 2014 Genopaver, LLC Research And Development Services	Jun. 30, 2013 Genopaver, LLC Research And Development Services	Jun. 30, 2014 Genopaver, LLC Research And Development Services	Jun. 30, 2013 Genopaver, LLC Research And Development Services	Feb. 14, 2013 AquaBounty ECC	Mar. 26, 2014 Intrexon Energy Partners, LLC	Jun. 30, 2014 Intrexon Energy Partners, LLC	Jun. 30, 2014 Intrexon Energy Partners, LLC	Jun. 30, 2014 Intrexon Energy Partners, LLC Upfront and Milestone Payments	Jun. 30, 2014 Intrexon Energy Partners, LLC Upfront and Milestone Payments	Jun. 30, 2014 Intrexon Energy Partners, LLC Research And Development Services	Jun. 30, 2014 Intrexon Energy Partners, LLC Research And Development Services	Jan. 06, 2011 Ziopharm Oncology, Inc.	Jun. 30, 2014 Ziopharm Oncology, Inc.	Jun. 30, 2013 Ziopharm Oncology, Inc.	Jun. 30, 2014 Ziopharm Oncology, Inc.	Jun. 30, 2013 Ziopharm Oncology, Inc.	Jan. 06, 2011 Ziopharm Oncology, Inc.	Jun. 30, 2014 Ziopharm Oncology, Inc. Upfront and Milestone Payments	Jun. 30, 2013 Ziopharm Oncology, Inc. Upfront and Milestone Payments	Jun. 30, 2014 Ziopharm Oncology, Inc. Upfront and Milestone Payments	Jun. 30, 2013 Ziopharm Oncology, Inc. Upfront and Milestone Payments	Jun. 30, 2014 Ziopharm Oncology, Inc. Research And Development Services	Jun. 30, 2013 Ziopharm Oncology, Inc. Research And Development Services	Jun. 30, 2014 Ziopharm Oncology, Inc. Research And Development Services	Jun. 30, 2013 Ziopharm Oncology, Inc. Research And Development Services	Nov. 18, 2011 Synthetic Biologics Field One ECC	Nov. 18, 2011 Synthetic Biologics Field One ECC	Sep. 30, 2013 S & I Ophthalmic, LLC	Jun. 30, 2014 S & I Ophthalmic, LLC	Jun. 30, 2014 S & I Ophthalmic, LLC	Jun. 30, 2014 S & I Ophthalmic, LLC Research And Development Services	Jun. 30, 2014 S & I Ophthalmic, LLC Research And Development Services	Dec. 18, 2013 OvaXon, LLC	Jun. 30, 2014 OvaXon, LLC	Jun. 30, 2014 OvaXon, LLC	Jun. 30, 2014 OvaXon, LLC Research And Development Services	Jun. 30, 2014 OvaXon, LLC Research And Development Services	Oct. 05, 2012 Upfront Synthetic Biologics Field Two ECC Upfront and Milestone Payments	Jun. 05, 2012 Upfront Oragenics ECC Upfront and Milestone Payments	Dec. 18, 2013 Upfront Oragenics Second ECC Upfront and Milestone Payments	Sep. 30, 2013 Upfront Oragenics Second ECC Upfront and Milestone Payments	Oct. 05, 2012 Upfront Fibrocell Science, Inc. Upfront and Milestone Payments	Mar. 29, 2013 Upfront Genopaver, LLC Upfront and Milestone Payments	Mar. 26, 2014 Upfront Intrexon Energy Partners, LLC Upfront and Milestone Payments	Jan. 06, 2011 Upfront Ziopharm Oncology, Inc. Upfront and Milestone Payments	Jan. 06, 2011 Upfront Ziopharm Oncology ECC Separate Unit of Accounting Upfront and Milestone Payments	Jan. 06, 2011 Upfront Ziopharm Oncology ECC Unit of Accounting One Upfront and Milestone Payments	Nov. 18, 2011 Upfront Synthetic Biologics Field One ECC Upfront and Milestone Payments	Jan. 10, 2014 Supplemental Upfront Fibrocell Science, Inc. Upfront and Milestone Payments	Jun. 28, 2013 Supplemental Upfront Fibrocell Science, Inc. Upfront and Milestone Payments	Oct. 24, 2012 Milestone One Ziopharm Oncology, Inc. Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, shares																																																																																																	3,552,210	4,392,425		1,348,000	1,317,520			3,636,926			3,123,558	1,024,590	1,243,781	3,636,926
Collaborative arrangement consideration received, value																																																																																																	$ 7,815	$ 6,588		$ 3,503	$ 7,576	$ 3,000	$ 25,000	$ 17,457			$ 1,687	$ 5,225	$ 7,612	$ 18,330
Collaboration revenue		11,764	6,674	19,601	10,538		2,517	2,751	4,399	3,888		9,247	3,923	15,202	6,650			193	1,980	552	2,550	163	1,666	325	1,861	30	314	227	689								1,331	773	2,641	1,361		448	158	896	316	883	615	1,745	1,045		491	281	981	281	68	68	137	68	423	213	844	213			1,835	1,835	625	625	1,210	1,210		4,341	2,935	7,021	5,009		644	644	1,288	1,288	3,697	2,291	5,733	3,721				607	1,486	607	1,486		579	748	579	748									1,115
Deferred revenue		99,453		99,453		73,571	98,233		98,233		72,207																			2,500																																																																												16,342
Percent of shares outstanding at the date of achievement of future milestone																																1.00%																																												7.495%										9.995%
Royalty rate as a percentage of net profit																															25.00%																																								50.00%														50.00%
Required notice period for voluntary termination of collaborative agreement																90 days															90 days		90 days			90 days														90 days														90 days							90 days														90 days		90 days					90 days
Consideration to be received upon achievement of future milestone 1																	2,000																	2,000
Consideration to be received upon achievement of future milestone 2																	3,000																	5,000
Field expansion fee																	2,000
Percentage of shares outstanding at the date of achievement of future milestone 2																																1.50%
Percentage of shares outstanding at the date of achievement of future milestone 3																																2.00%
Percentage of shares outstanding at the date of achievement of future milestone 4																																2.50%
Percentage of shares outstanding at the date of achievement of future milestone 5																																3.00%
Maturity date of promissory note																																																																																																				December 31, 2013
Collaborative arrangement consideration received, value of convertible promissory note																																																																																																				1,956
Consideration to be received upon achievement of future milestone 3																																		10,000
Royalty rate as a percentage of net sales, tier 1																																	10.00%			7.00%
Conversion of promissory note into Common stock																																																																																																			698,241
Reverse stock split ratio	1-for-1.75																																		1-for-25
Reverse stock split ratio	0.57143																																		0.04
Royalty rate as a percentage of net sales, tier 2																																				14.00%
Royalty rate of savings from improvement																																				33.00%
Level of net sales at which royalty rate changes to tier 2																																									$ 25,000
Royalty rate as a percentage of gross profit																																																															16.66%